Wen-xing Qin

Changzheng, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial.

Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial.

Journal: Signal transduction and targeted therapy

Published: January 12, 2025

Impact of molecular tumor board on clinical outcomes in patients with refractory solid tumors: a real-world study.

Impact of molecular tumor board on clinical outcomes in patients with refractory solid tumors: a real-world study.

Journal: The oncologist

Published: April 01, 2024

Impact of Molecular Tumor Board on Clinical Outcomes in Patients with Refractory Solid Tumor: a Real-World Study.

Impact of Molecular Tumor Board on Clinical Outcomes in Patients with Refractory Solid Tumor: a Real-World Study.

Journal: The oncologist

Published: April 01, 2024

Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial.

Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial.

Journal: International journal of cancer

Published: January 19, 2023

Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).

Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).

Journal: Frontiers in oncology

Published: January 23, 2022

Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.

Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 17, 2021

Primary squamous cell carcinoma of pancreas: a population-based study.

Primary squamous cell carcinoma of pancreas: a population-based study.

Journal: Gland surgery

Published: April 12, 2021

The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer.

The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer.

Journal: Critical reviews in oncology/hematology

Published: November 06, 2019

Basket Trials for Intractable Cancer.

Basket Trials for Intractable Cancer.

Journal: Frontiers in oncology

Published: January 14, 2019

Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.

Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.

Journal: Clinica chimica acta; international journal of clinical chemistry

Published: August 25, 2018

The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review.

The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review.

Journal: OncoTargets and therapy

Published: August 22, 2018

Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways.

Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways.

Journal: Oncology letters

Published: January 04, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026